Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for NVCR

Stock Name	Novocure Ltd
Ticker	NVCR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	JE00BYSS4X48
LEI	213800YPP55UMHWA4826

Show aggregate NVCR holdings

News associated with NVCR

NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $12.28, but opened at $13.65. NovoCure shares last traded at $13.03, with a volume of 543,802 shares trading hands. Specifically, CEO Ashley Cordova acquired 81,550 shares of the […] - 2025-09-10 02:26:51
Analysts Set NovoCure Limited (NASDAQ:NVCR) Price Target at $28.79: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average […] - 2025-08-21 04:44:51
Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer: (RTTNews) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. - 2025-08-20 08:50:20
TD Asset Management Inc Sells 204,942 Shares of NovoCure Limited (NASDAQ:NVCR): TD Asset Management Inc decreased its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 81.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 48,212 shares of the medical equipment provider’s stock after selling 204,942 shares during the period. TD Asset Management Inc’s holdings in NovoCure […] - 2025-08-05 04:37:19
Y Intercept Hong Kong Ltd Has $419,000 Stock Position in NovoCure Limited (NASDAQ:NVCR): Y Intercept Hong Kong Ltd raised its stake in NovoCure Limited (NASDAQ:NVCR – Free Report) by 25.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,492 shares of the medical equipment provider’s stock after buying an additional 4,723 shares during […] - 2025-07-29 05:56:52
NovoCure (NASDAQ:NVCR) Receives “Equal Weight” Rating from Wells Fargo & Company: Wells Fargo & Company reissued their equal weight rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday morning, Marketbeat reports. The firm currently has a $14.50 target price on the medical equipment provider’s stock, down from their previous target price of $40.00. Other analysts also recently issued reports about […] - 2025-07-28 04:18:52
Bank of New York Mellon Corp Purchases 2,062 Shares of NovoCure Limited (NASDAQ:NVCR): Bank of New York Mellon Corp grew its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,592 shares of the medical equipment provider’s stock after acquiring an […] - 2025-07-25 04:35:07
32,179 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Jennison Associates LLC: Jennison Associates LLC acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,179 shares of the medical equipment provider’s stock, valued at approximately $573,000. Several other large investors also […] - 2025-07-23 06:20:54
Teacher Retirement System of Texas Acquires 3,123 Shares of NovoCure Limited (NASDAQ:NVCR): Teacher Retirement System of Texas raised its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 62,375 shares of the medical equipment provider’s stock after purchasing an additional 3,123 shares during the quarter. Teacher Retirement System of Texas’ holdings in NovoCure were worth […] - 2025-07-14 04:56:53
LADENBURG THALM/SH SH Begins Coverage on NovoCure (NASDAQ:NVCR): LADENBURG THALM/SH SH began coverage on shares of NovoCure (NASDAQ:NVCR – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the medical equipment provider’s stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 64.93% from the […] - 2025-07-10 04:01:26
California State Teachers Retirement System Sells 635 Shares of NovoCure Limited (NASDAQ:NVCR): California State Teachers Retirement System reduced its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,389 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. California […] - 2025-06-06 05:42:57
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […] - 2025-06-04 03:06:44
BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR): BNP Paribas Financial Markets decreased its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 83.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,555 shares of the medical equipment provider’s stock after selling 147,371 shares during the period. BNP Paribas Financial Markets’ holdings in NovoCure were worth $851,000 as of […] - 2025-05-22 04:38:53
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AG: Deutsche Bank AG lifted its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,327 shares of the medical equipment provider’s stock after acquiring an additional 33,293 shares during the quarter. Deutsche Bank […] - 2025-05-19 05:06:55
Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR): Tower Research Capital LLC TRC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,034 shares of the medical equipment provider’s stock after selling 6,669 shares […] - 2025-05-12 04:50:52
NovoCure (NASDAQ:NVCR) and Meihua International Medical Technologies (NASDAQ:MHUA) Head to Head Survey: Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 1.2% of […] - 2025-05-06 02:09:04
Why NovoCure Stock Skyrocketed This Week: Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. - 2025-04-25 14:21:57
Bank of Montreal Can Acquires New Shares in NovoCure Limited (NASDAQ:NVCR): Bank of Montreal Can purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,183 shares of the medical equipment provider’s stock, valued at approximately $244,000. Other institutional investors have also made changes to their positions in the company. Tidal Investments LLC […] - 2025-04-25 05:08:56
Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price: NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […] - 2025-04-25 04:31:12
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com: NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other research analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of NovoCure from $42.00 to $34.00 and set an “overweight” […] - 2025-04-25 03:10:53
NovoCure Surpasses Q1 Expectations: NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s e - 2025-04-24 10:25:13
Legal & General Group Plc Reduces Stake in NovoCure Limited (NASDAQ:NVCR): Legal & General Group Plc cut its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 157,758 shares of the medical equipment provider’s stock after selling 26,654 shares during the quarter. Legal & General Group Plc’s holdings in NovoCure were worth $4,701,000 […] - 2025-04-22 05:44:56
Summit Investment Advisors Inc. Raises Stock Holdings in NovoCure Limited (NASDAQ:NVCR): Summit Investment Advisors Inc. boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,141 shares of the medical equipment provider’s stock after acquiring an additional 708 shares […] - 2025-04-21 04:56:57
StockNews.com Downgrades NovoCure (NASDAQ:NVCR) to Sell: NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday. Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares […] - 2025-04-11 05:18:59
Pictet Asset Management Holding SA Boosts Stake in NovoCure Limited (NASDAQ:NVCR): Pictet Asset Management Holding SA boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,919 shares of the medical equipment provider’s stock after acquiring an additional […] - 2025-04-10 05:37:15
21,600 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in NovoCure Limited (NASDAQ:NVCR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,600 shares of the medical equipment provider’s stock, valued at approximately $644,000. A number of other hedge funds have also modified their holdings of […] - 2025-04-02 05:16:54
NovoCure Limited (NASDAQ:NVCR) Receives $35.80 Consensus PT from Analysts: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-03-24 04:40:48
NovoCure (NASDAQ:NVCR) Raised to “Hold” at StockNews.com: NovoCure (NASDAQ:NVCR – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday. Other analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of NovoCure in a […] - 2025-03-20 03:44:55
Charles Schwab Investment Management Inc. Purchases 11,771 Shares of NovoCure Limited (NASDAQ:NVCR): Charles Schwab Investment Management Inc. boosted its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 836,214 shares of the medical equipment provider’s stock after buying an additional 11,771 shares during the period. […] - 2025-03-19 05:52:57
SBI Securities Co. Ltd. Invests $70,000 in NovoCure Limited (NASDAQ:NVCR): SBI Securities Co. Ltd. acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,341 shares of the medical equipment provider’s stock, valued at approximately $70,000. Several other institutional investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group bought […] - 2025-03-10 06:07:07

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) NVCR holdings

Date	Number of NVCR Shares Held	Base Market Value of NVCR Shares	Local Market Value of NVCR Shares	Change in NVCR Shares Held	Change in NVCR Base Value	Current Price per NVCR Share Held	Previous Price per NVCR Share Held
2025-12-03 (Wednesday)	77,729	USD 917,979	USD 917,979	0	USD 69,178	USD 11.81	USD 10.92
2025-12-02 (Tuesday)	77,729	USD 848,801	USD 848,801	2,790	USD -26,487	USD 10.92	USD 11.68
2025-12-01 (Monday)	74,939	USD 875,288	USD 875,288	0	USD -84,681	USD 11.68	USD 12.81
2025-11-28 (Friday)	74,939	USD 959,969	USD 959,969	186	USD 6,121	USD 12.81	USD 12.76
2025-11-27 (Thursday)	74,753	USD 953,848	USD 953,848	0	USD 0	USD 12.76	USD 12.76
2025-11-26 (Wednesday)	74,753	USD 953,848	USD 953,848	558	USD 16,023	USD 12.76	USD 12.64
2025-11-25 (Tuesday)	74,195	USD 937,825	USD 937,825	930	USD 19,815	USD 12.64	USD 12.53
2025-11-24 (Monday)	73,265	USD 918,010	USD 918,010	186	USD 44,716	USD 12.53	USD 11.95
2025-11-21 (Friday)	73,079	USD 873,294	USD 873,294	0	USD 35,809	USD 11.95	USD 11.46
2025-11-20 (Thursday)	73,079	USD 837,485	USD 837,485	-740	USD -7,743	USD 11.46	USD 11.45
2025-11-19 (Wednesday)	73,819	USD 845,228	USD 845,228	185	USD 2,119	USD 11.45	USD 11.45
2025-11-18 (Tuesday)	73,634	USD 843,109	USD 843,109	1,110	USD 25,764	USD 11.45	USD 11.27
2025-11-17 (Monday)	72,524	USD 817,345	USD 817,345	370	USD 562	USD 11.27	USD 11.32

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NVCR by Blackrock for IE00BDZVHG35

Show aggregate share trades of NVCR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 2,790 11.820 10.790 10.893 USD 30,391 17.72
2025-11-28 BUY 186 12.890 12.610 12.638 USD 2,351 17.78
2025-11-26 BUY 558 12.820 12.525 12.554 USD 7,005 17.83
2025-11-26 BUY 558 12.820 12.525 12.554 USD 7,005 17.83
2025-11-25 BUY 930 12.680 12.450 12.473 USD 11,600 17.85
2025-11-24 BUY 186 12.560 11.920 11.984 USD 2,229 17.88
2025-11-20 SELL -740 11.460* 17.94 Profit of 13,277 on sale
2025-11-19 BUY 185 11.450* 17.98
2025-11-18 BUY 1,110 11.450* 18.01
2025-11-17 BUY 370 11.435 11.120 11.151 USD 4,126 18.04
2025-11-14 BUY 185 11.665 11.200 11.246 USD 2,081 18.08
2025-11-12 BUY 185 11.965 11.330 11.393 USD 2,108 18.15
2025-11-10 BUY 185 11.270 10.890 10.928 USD 2,022 18.22
2025-11-06 BUY 184 11.500 11.240 11.266 USD 2,073 18.29
2025-11-04 BUY 185 12.214 11.860 11.895 USD 2,201 18.36
2025-10-30 BUY 925 14.220 12.725 12.875 USD 11,909 18.46
2025-10-29 BUY 370 13.480 13.705 13.682 USD 5,063 18.49
2025-10-22 SELL -740 13.860 14.435 14.378 USD -10,639 18.62 Profit of 3,141 on sale
2025-10-20 BUY 370 14.480 14.580 14.570 USD 5,391 18.67
2025-10-17 BUY 923 13.780 14.128 14.093 USD 13,008 18.70
2025-10-15 BUY 1,472 14.180 14.190 14.189 USD 20,886 18.73
2025-10-03 BUY 1,295 14.660 14.690 14.687 USD 19,020 18.78
2025-10-02 BUY 185 14.050 14.120 14.113 USD 2,611 18.81
2025-09-30 BUY 370 12.920 13.040 13.028 USD 4,820 18.88
2025-09-26 BUY 370 12.890 13.000 12.989 USD 4,806 18.95
2025-09-25 BUY 370 12.780 12.840 12.834 USD 4,749 18.99
2025-09-18 BUY 193 13.000 13.110 13.099 USD 2,528 19.02
2025-09-17 BUY 579 12.690 13.240 13.185 USD 7,634 19.06
2025-09-11 SELL -193 12.730 12.830 12.820 USD -2,474 19.14 Profit of 1,220 on sale
2025-09-10 BUY 384 12.210 12.750 12.696 USD 4,875 19.18
2025-07-17 SELL -382 16.210 16.814 16.754 USD -6,400 19.29 Profit of 967 on sale
2025-07-11 SELL -1,528 17.600 18.250 18.185 USD -27,787 19.34 Profit of 1,771 on sale
2025-07-02 BUY 10,505 17.880 18.300 18.258 USD 191,800 19.38
2025-06-25 BUY 382 17.325 17.350 17.348 USD 6,627 19.43
2025-06-20 BUY 1,686 16.690 17.070 17.032 USD 28,716 19.49
2025-06-13 BUY 1,498 17.550 17.970 17.928 USD 26,856 19.57
2025-06-11 BUY 362 17.360 18.560 18.440 USD 6,675 19.59
2025-06-10 BUY 362 18.380 19.250 19.163 USD 6,937 19.60
2025-06-04 SELL -181 16.720 17.260 17.206 USD -3,114 19.69 Profit of 450 on sale
2025-04-23 BUY 181 17.770 17.810 17.806 USD 3,223 20.20
2025-04-10 SELL -1,440 16.080 16.870 16.791 USD -24,179 20.62 Profit of 5,515 on sale
2025-04-08 SELL -180 15.370 17.190 17.008 USD -3,061 20.72 Profit of 669 on sale
2025-04-07 SELL -180 16.610 17.403 17.324 USD -3,118 20.77 Profit of 621 on sale
2025-04-04 SELL -905 16.490 16.800 16.769 USD -15,176 20.82 Profit of 3,668 on sale
2025-04-01 BUY 756 17.520 18.000 17.952 USD 13,572 20.90
2025-03-31 SELL -543 17.820 18.580 18.504 USD -10,048 20.93 Profit of 1,319 on sale
2025-03-21 BUY 3,174 19.330 19.500 19.483 USD 61,839 21.08
2025-03-14 SELL -2,736 19.490 20.485 20.386 USD -55,775 21.20 Profit of 2,238 on sale
2025-03-07 SELL -342 20.180 20.500 20.468 USD -7,000 21.26 Profit of 270 on sale
2025-03-04 SELL -171 18.190 18.450 18.424 USD -3,151 21.37 Profit of 504 on sale
2025-02-25 BUY 342 21.000 21.400 21.360 USD 7,305 21.50
2025-02-19 SELL -170 21.810 22.200 22.161 USD -3,767 21.48 Loss of -116 on sale
2025-02-13 BUY 510 21.710 21.820 21.809 USD 11,123 21.42
2025-02-12 BUY 170 21.370 21.400 21.397 USD 3,637 21.43
2025-02-11 BUY 680 21.210 21.660 21.615 USD 14,698 21.43
2024-12-30 SELL -5,673 30.080 30.810 30.737 USD -174,371 19.71 Loss of -62,582 on sale
2024-11-18 SELL -2,775 15.730 16.160 16.117 USD -44,725 16.74 Profit of 1,720 on sale
2024-11-08 SELL -185 17.440 18.670 18.547 USD -3,431 16.61 Loss of -358 on sale
2024-10-21 SELL -186 16.270 17.070 16.990 USD -3,160 0.00 Loss of -3,160 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	2,790	11.820	10.790	10.893	USD 30,391	17.72
2025-11-28	BUY	186	12.890	12.610	12.638	USD 2,351	17.78
2025-11-26	BUY	558	12.820	12.525	12.554	USD 7,005	17.83
2025-11-26	BUY	558	12.820	12.525	12.554	USD 7,005	17.83
2025-11-25	BUY	930	12.680	12.450	12.473	USD 11,600	17.85
2025-11-24	BUY	186	12.560	11.920	11.984	USD 2,229	17.88
2025-11-20	SELL	-740			11.460*		17.94 Profit of 13,277 on sale
2025-11-19	BUY	185			11.450*		17.98
2025-11-18	BUY	1,110			11.450*		18.01
2025-11-17	BUY	370	11.435	11.120	11.151	USD 4,126	18.04
2025-11-14	BUY	185	11.665	11.200	11.246	USD 2,081	18.08
2025-11-12	BUY	185	11.965	11.330	11.393	USD 2,108	18.15
2025-11-10	BUY	185	11.270	10.890	10.928	USD 2,022	18.22
2025-11-06	BUY	184	11.500	11.240	11.266	USD 2,073	18.29
2025-11-04	BUY	185	12.214	11.860	11.895	USD 2,201	18.36
2025-10-30	BUY	925	14.220	12.725	12.875	USD 11,909	18.46
2025-10-29	BUY	370	13.480	13.705	13.682	USD 5,063	18.49
2025-10-22	SELL	-740	13.860	14.435	14.378	USD -10,639	18.62 Profit of 3,141 on sale
2025-10-20	BUY	370	14.480	14.580	14.570	USD 5,391	18.67
2025-10-17	BUY	923	13.780	14.128	14.093	USD 13,008	18.70
2025-10-15	BUY	1,472	14.180	14.190	14.189	USD 20,886	18.73
2025-10-03	BUY	1,295	14.660	14.690	14.687	USD 19,020	18.78
2025-10-02	BUY	185	14.050	14.120	14.113	USD 2,611	18.81
2025-09-30	BUY	370	12.920	13.040	13.028	USD 4,820	18.88
2025-09-26	BUY	370	12.890	13.000	12.989	USD 4,806	18.95
2025-09-25	BUY	370	12.780	12.840	12.834	USD 4,749	18.99
2025-09-18	BUY	193	13.000	13.110	13.099	USD 2,528	19.02
2025-09-17	BUY	579	12.690	13.240	13.185	USD 7,634	19.06
2025-09-11	SELL	-193	12.730	12.830	12.820	USD -2,474	19.14 Profit of 1,220 on sale
2025-09-10	BUY	384	12.210	12.750	12.696	USD 4,875	19.18
2025-07-17	SELL	-382	16.210	16.814	16.754	USD -6,400	19.29 Profit of 967 on sale
2025-07-11	SELL	-1,528	17.600	18.250	18.185	USD -27,787	19.34 Profit of 1,771 on sale
2025-07-02	BUY	10,505	17.880	18.300	18.258	USD 191,800	19.38
2025-06-25	BUY	382	17.325	17.350	17.348	USD 6,627	19.43
2025-06-20	BUY	1,686	16.690	17.070	17.032	USD 28,716	19.49
2025-06-13	BUY	1,498	17.550	17.970	17.928	USD 26,856	19.57
2025-06-11	BUY	362	17.360	18.560	18.440	USD 6,675	19.59
2025-06-10	BUY	362	18.380	19.250	19.163	USD 6,937	19.60
2025-06-04	SELL	-181	16.720	17.260	17.206	USD -3,114	19.69 Profit of 450 on sale
2025-04-23	BUY	181	17.770	17.810	17.806	USD 3,223	20.20
2025-04-10	SELL	-1,440	16.080	16.870	16.791	USD -24,179	20.62 Profit of 5,515 on sale
2025-04-08	SELL	-180	15.370	17.190	17.008	USD -3,061	20.72 Profit of 669 on sale
2025-04-07	SELL	-180	16.610	17.403	17.324	USD -3,118	20.77 Profit of 621 on sale
2025-04-04	SELL	-905	16.490	16.800	16.769	USD -15,176	20.82 Profit of 3,668 on sale
2025-04-01	BUY	756	17.520	18.000	17.952	USD 13,572	20.90
2025-03-31	SELL	-543	17.820	18.580	18.504	USD -10,048	20.93 Profit of 1,319 on sale
2025-03-21	BUY	3,174	19.330	19.500	19.483	USD 61,839	21.08
2025-03-14	SELL	-2,736	19.490	20.485	20.386	USD -55,775	21.20 Profit of 2,238 on sale
2025-03-07	SELL	-342	20.180	20.500	20.468	USD -7,000	21.26 Profit of 270 on sale
2025-03-04	SELL	-171	18.190	18.450	18.424	USD -3,151	21.37 Profit of 504 on sale
2025-02-25	BUY	342	21.000	21.400	21.360	USD 7,305	21.50
2025-02-19	SELL	-170	21.810	22.200	22.161	USD -3,767	21.48 Loss of -116 on sale
2025-02-13	BUY	510	21.710	21.820	21.809	USD 11,123	21.42
2025-02-12	BUY	170	21.370	21.400	21.397	USD 3,637	21.43
2025-02-11	BUY	680	21.210	21.660	21.615	USD 14,698	21.43
2024-12-30	SELL	-5,673	30.080	30.810	30.737	USD -174,371	19.71 Loss of -62,582 on sale
2024-11-18	SELL	-2,775	15.730	16.160	16.117	USD -44,725	16.74 Profit of 1,720 on sale
2024-11-08	SELL	-185	17.440	18.670	18.547	USD -3,431	16.61 Loss of -358 on sale
2024-10-21	SELL	-186	16.270	17.070	16.990	USD -3,160	0.00 Loss of -3,160 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NVCR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	146,296	0	421,759	34.7%
2025-09-18	109,188	0	560,456	19.5%
2025-09-17	119,469	301	498,067	24.0%
2025-09-16	191,175	400	705,469	27.1%
2025-09-15	272,067	0	1,107,083	24.6%
2025-09-12	109,857	0	270,874	40.6%
2025-09-11	218,116	0	689,642	31.6%
2025-09-10	230,953	95	658,890	35.1%
2025-09-09	234,044	4,681	645,307	36.3%
2025-09-08	339,725	3,440	815,445	41.7%
2025-09-05	166,892	0	408,146	40.9%
2025-09-04	257,672	43,716	678,816	38.0%
2025-09-03	177,114	0	351,319	50.4%
2025-09-02	137,400	0	404,389	34.0%
2025-08-29	160,727	0	352,263	45.6%
2025-08-28	191,578	3,553	657,423	29.1%
2025-08-27	150,551	7,255	425,992	35.3%
2025-08-26	119,516	0	645,276	18.5%
2025-08-25	171,812	0	553,315	31.1%
2025-08-22	94,300	0	476,262	19.8%
2025-08-21	143,620	0	367,651	39.1%
2025-08-20	190,862	110	434,326	43.9%
2025-08-19	137,859	0	457,522	30.1%
2025-08-18	179,056	0	473,961	37.8%
2025-08-15	169,569	8	564,351	30.0%
2025-08-14	212,081	0	504,691	42.0%
2025-08-13	268,074	0	1,199,258	22.4%
2025-08-12	212,713	4,365	614,711	34.6%
2025-08-11	194,203	4	512,173	37.9%
2025-08-08	254,996	1,239	736,775	34.6%
2025-08-07	243,762	608	804,784	30.3%
2025-08-06	229,740	3,802	734,190	31.3%
2025-08-05	463,496	1,061	2,536,451	18.3%
2025-08-04	323,993	53	954,167	34.0%
2025-08-01	378,472	0	1,053,485	35.9%
2025-07-31	479,008	2,516	1,888,144	25.4%
2025-07-30	452,345	0	1,441,401	31.4%
2025-07-29	329,608	1,502	1,070,202	30.8%
2025-07-28	306,605	0	1,104,404	27.8%
2025-07-25	533,024	42,563	1,609,831	33.1%
2025-07-24	763,758	71,574	2,115,331	36.1%
2025-07-23	145,473	921	417,907	34.8%
2025-07-22	113,998	0	328,855	34.7%
2025-07-21	140,312	0	474,581	29.6%
2025-07-18	96,636	400	339,936	28.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE